Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Purpose
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Conditions
- Aging
- Diabetes Mellitus, Type 2
- PreDiabetes
- Overweight and Obesity
Eligibility
- Eligible Ages
- Between 65 Years and 90 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Older than 65 - Have prediabetes or diabetes - BMI ≥ 27.0 kg/m2 - Living independently (not in assisted living or nursing home)
Exclusion Criteria
- Have heart disease - Have liver disease - Smoke
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Semaglutide and lifestyle intervention |
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks. |
|
Active Comparator Lifestyle intervention |
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program |
|
More Details
- Status
- Active, not recruiting
- Sponsor
- The University of Texas Health Science Center at San Antonio